#	Pagina
attuale pagina	/open-h2020/projects/211126/index.html
-1	/open-h2020/projects/215800/index.html
-2	/open-fp7/projects/100070/index.html

Opendata, web and dolomites

ColoFast SIGNED

Developing a Non-Invasive Kit for Early Colorectal Cancer Detection

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ColoFast project word cloud

Explore the words cloud of the ColoFast project. It provides you a very rough idea of what is the project "ColoFast" about.

edge multiplying fulfill treatment cohorts services reduce cancer blood benefit 25 18 quality programs colofasttm 616m company size profit biomarkers care rate business commercialize 41 look generation screening unmet colofast colorectal majority easily amadix prospective 2024 patient agrees invasive sme people opportunity decreasing clinical priorities population profitable prevented clear routine crc health medical global specificity commercialization employees survival 2m life worldwide sensitivity japan 189m mortality regulatory avings 2020 healthcare reducing team patients deaths kit earlier acceptance assisting diagnosed savings detection approved market diagnosis hospitals give community validate huge improvements turnover national showed strategies expanding 2021

Project "ColoFast" data sheet

The following table provides information about the project.

Coordinator	ADVANCED MARKER DISCOVERY SL Organization address address: CALLE ACERA DE RECOLETOS 2 1 B city: VALLADOLID postcode: 47004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.amadix.com/colofast/
Total cost	2˙817˙154 €
EC max contribution	2˙817˙154 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2017
Duration (year-month-day)	from 2017-07-01 to 2021-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ADVANCED MARKER DISCOVERY SL ADVANCED MARKER DISCOVERY SL Organization address address: CALLE ACERA DE RECOLETOS 2 1 B city: VALLADOLID postcode: 47004 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALLADOLID)	coordinator	2˙817˙154.00

Map

Project objective

Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths could be prevented by adequate screening programs for early detection. European authorities look for new strategies to address the clinical need for early diagnosis of CRC that will reduce patient care associated costs. Potential savings would be achieved if CRC patients were diagnosed earlier. The objective of this proposal is to validate and commercialize a novel, non-invasive, simple to use kit (ColoFastTM), regulatory approved for the diagnosis of CRC in blood. It is based on a new generation of leading-edge biomarkers that showed very high sensitivity and specificity for early detection of CRC in two prospective cohorts. The commercialization of the kit will have clear impact in improving survival of patients and reducing mortality by CRC cancer, with significant costsavings for National Health Services. It will be easily implemented in the clinical routine of the majority of European hospitals, with better acceptance of patients. ColoFast represents a significant business opportunity, addressing a clear unmet medical need in a large and expanding target population of 189M people in Europe in 2020, growing at 25%, with a significant global market of €1,616M in Europe, the US and Japan this year. It will have a huge impact on the growth of a SME as Amadix over the next 10 years, multiplying the team size by five in five years (41 employees in 2020). 2M European people will benefit from the test in 2024. Amadix turnover in 2021 will be €18 m, which will give our company a profit of €7 m in 2021. From this year on the company will be profitable. Overall, ColoFast will reduce mortality rate and treatment cost while improving quality of life in a cost-effective way, assisting also to fulfill European priorities for healthcare improvements.

Deliverables

List of deliverables.
Research data management plan	Documents, reports	2020-01-27 14:54:22
1st Dissemination and Communication Plan:	Documents, reports	2020-01-27 14:54:22

Take a look to the deliverables list in detail: detailed list of ColoFast deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOFAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOFAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination